Skip to Content
Contact DCTD
Show menu
Search this site
Last Updated: 10/25/2022

DCTD’s Translational Research Program (TRP) Announces Fiscal Year 2022 SPORE Grantees

DCTD’s Translational Research Program (TRP) Announces Fiscal Year 2022 SPORE Grantees

The TRP recently announced its successfully competed FY2022 Specialized Programs of Research Excellence (SPORE) grantees.

The SPORE program uses the P50 and U54 grant funding mechanisms to promote collaborative, interdisciplinary, translational cancer multi-project research. SPOREs are primarily focused on organ site disease, but also on themes that cut across organ sites.

There are now 60 funded SPOREs located at academic centers in 21 states. See information about all SPOREs by organ site and by state.

FY 2022 SPORE Grantees

Principal Investigator Institution Cancer Type
*Grant Renewal
Laurence Howard Baker (contact) and Scott Michael Schuetze University of Michigan, Ann Arbor Sarcoma
David A. Barbie (contact) and Lecia V. Sequist Dana-Farber Cancer Institute Lung
James Brugarolas (contact) and Payal Kapur* University of Texas, Southwestern Medical Center Kidney
Robert L. Ferris (contact) and Heath Devin Skinner* University of Pittsburgh Head & Neck
Matthew Goetz* Mayo Clinic, Rochester Breast
Paul M. Harari* University of Wisconsin, Madison Head & Neck
Helen E. Heslop (contact) and Malcolm K. Brenner* Baylor College of Medicine Lymphoma
Linda M. Liau* University of California, Los Angeles Brain
Eileen Mary O’Reilly (contact) Sloan Kettering Institute for Cancer Research Pancreas
Howard I. Scher (contact) and Yu Chen* Sloan Kettering Institute for Cancer Research Prostate
Jen Jen Yeh University of North Carolina Pancreas

Goals of the SPORE Program

  • Translating novel scientific discoveries from the laboratory and/or population studies to the clinic for testing in humans with cancer or at risk for cancer
  • Determining the biological basis for clinical observations
  • Using specimens from clinical studies to determine correlations between biomarkers and outcomes in patients
  • Promoting collaborations between SPOREs, Cancer Centers, other NCI/NIH funded mechanisms and programs, and outside organizations
  • Promoting pilot projects and career enhancement of researchers new to translational research
  • Supporting research in high incidence and rare cancers
  • Encouraging communication with advocates and advocate organizations to obtain advice from the patient perspective

Contact TRP staff for more information on the SPORE program.